Explore 3 Stock Ideas & Industry Insights Download Free Report

Cyteir Therapeutics Inc

Company price
3.01 USD -0.01 ( 0.33%)
Last update at 2024-04-12T13:30:00Z
Market Cap
109.79M

Momentum Score

…

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.01
Low
3.01
High
52 Week Price Range
1.37
Low
3.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-16.59M
Debt / Equity
0.01
ROE
-23.81%
Net Debt
-146.23M
ROCE
-33.02%
Diluted EPS TTM
-0.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -46.06M -42.13M -20.82M -15.04M
Net income -43.95M -41.65M -20.82M -15.04M
Selling general administrative 13.55M 11.30M 4.18M 3.35M
Reconciled depreciation 0.67M 0.48M 0.35M 0.21M
Ebit -48.84M -42.74M -20.94M -16.11M
Ebitda -48.17M -42.26M -20.59M -15.89M
Depreciation and amortization 0.67M 0.48M 0.35M 0.21M
Non operating income net other 2.11M 0.13M - -
Operating income -48.17M -42.26M -20.94M -16.11M
Other operating expenses 48.17M 42.26M 20.94M 16.11M
Interest expense 0.67M 0.48M 0.00M 0.00M
Income tax expense -2.11M -0.48M -0.12M -1.06M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 48.17M 42.26M 20.94M 16.11M
Total other income expense net 2.11M 0.13M 0.12M 1.06M
Net income from continuing ops -46.06M -42.13M -20.82M -15.04M
Net income applicable to common shares -46.06M -42.13M -20.82M -15.04M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 153.23M 195.39M 13.73M 31.37M
Other current assets 2.09M 3.35M 1.13M 0.00M
Total liab 6.95M 8.10M 61.77M 59.70M
Total stockholder equity 146.29M 187.29M -48.03M -28.34M
Deferred long term liab - 0.38M 0.06M -
Other current liab 3.30M 5.73M 1.45M 1.37M
Common stock 0.04M 0.04M 0.00M 0.00M
Capital stock 0.04M 0.04M 0.00M 0.00M
Retained earnings -138.11M -92.05M -49.93M -29.10M
Other liab - 0.58M 1.22M 0.32M
Other assets - 0.26M 0.32M 0.14M
Cash 147.12M 189.72M 10.94M 29.01M
Total current liabilities 5.32M 7.51M 3.14M 1.97M
Net debt -146.23M -189.72M -10.94M -29.01M
Short term debt 0.89M - - -
Short long term debt total 0.89M - - -
Other stockholder equity 284.37M 279.31M 1.89M 0.77M
Property plant equipment 1.70M 2.06M 1.29M 0.79M
Total current assets 149.21M 193.08M 12.13M 30.44M
Net tangible assets 146.29M 187.29M -48.03M -28.34M
Net receivables - 0.04M 0.06M 0.16M
Inventory - -0.04M - 1.26M
Accounts payable 1.13M 1.78M 1.69M 0.60M
Accumulated other comprehensive income - -195.39M - -
Common stock total equity 0.04M 0.04M 0.00M 0.00M
Retained earnings total equity -138.11M -92.05M - -
Non currrent assets other 2.32M 0.26M 0.32M 0.14M
Non current assets total 4.02M 2.31M 1.60M 0.93M
Capital lease obligations 0.89M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.31M -1.19M -0.85M -0.13M
Change to liabilities -3.72M 4.32M 1.03M -0.88M
Total cashflows from investing activities -0.31M -1.19M -0.85M -0.13M
Total cash from financing activities 0.24M 216.01M 1.43M 36.89M
Change to operating activities -1.87M 2.11M 0.44M -1.28M
Net income -46.06M -42.13M -20.82M -15.04M
Change in cash -42.60M 178.78M -17.96M 19.20M
Begin period cash flow 189.98M 11.19M 29.16M 9.96M
End period cash flow 147.38M 189.98M 11.19M 29.16M
Total cash from operating activities -42.53M -36.03M -18.54M -17.56M
Issuance of capital stock 0.00M 215.78M 0.00M 36.62M
Depreciation 0.67M 0.48M 0.35M 0.21M
Sale purchase of stock 0.24M 216.01M - -
Other cashflows from financing activities 0.18M 79.89M -0.85M -0.13M
Change to netincome 4.68M 3.46M 0.47M -0.57M
Capital expenditures 0.31M 1.19M 0.85M 0.13M
Cash flows other operating 1.90M -2.17M - -
Cash and cash equivalents changes -42.60M 178.78M - -
Change in working capital -2.53M 2.15M 1.47M -2.16M
Stock based compensation 4.68M 3.46M 0.47M 0.25M
Other non cash items 0.71M 10.96M 20.94M -0.81M
Free cash flow -42.84M -37.22M -19.39M -17.69M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CYT
Cyteir Therapeutics Inc
-0.01
0.33%
3.01 - - - 0.89 0.41
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Cyteir Therapeutics Inc

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

128 Spring Street, Lexington, MA, United States, 02421

857 285 4140

46

Name Title Year Born
Mr. Joseph S. Zakrzewski Independent Investor & Independent Chairman 1962
Dr. Markus F. Renschler M.D. Pres, CEO & Director 1961
Mr. Timothy Romberger Independent Director 1972
Dr. Paul Secrist Ph.D. Chief Scientific Officer 1966
Mr. Andrew W. Gengos Chief Bus. Officer & Sec. 1964
Dr. Kevin Mills Ph.D. Co-Founder NA
Mr. David G. Gaiero VP of Fin. 1979
Ms. Lisa A. Hayes VP of Investor Relations & Corp. Communications NA
Mr. Adam M. Veness Esq. Gen. Counsel 1986
Ms. Gale Cohen VP of HR NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…